Home / News / Research & Clinical Trials

Scientists Develop Artificial Intelligence for Mesothelioma Assessment

Research & Clinical Trials

Written by Tim Povtak

Fact Checked

Cite This Article

Reading Time: 3 mins

Publication Date: 04/26/2021

Asbestos.com is the nation’s most trusted mesothelioma resource

The Mesothelioma Center at Asbestos.com has provided patients and their loved ones the most updated and reliable information on mesothelioma and asbestos exposure since 2006.

Our team of Patient Advocates includes a medical doctor, a registered nurse, health services administrators, veterans, VA-accredited Claims Agents, an oncology patient navigator and hospice care expert. Their combined expertise means we help any mesothelioma patient or loved one through every step of their cancer journey.

More than 30 contributors, including mesothelioma doctors, survivors, health care professionals and other experts, have peer-reviewed our website and written unique research-driven articles to ensure you get the highest-quality medical and health information.

About The Mesothelioma Center at Asbestos.com

Assisting mesothelioma patients and their loved ones since 2006.
Helps more than 50% of mesothelioma patients diagnosed annually in the U.S.
A+ rating from the Better Business Bureau.
5-star reviewed mesothelioma and support organization.

Learn More About Us

Testimonials

"My family has only the highest compliment for the assistance and support that we received from The Mesothelioma Center. This is a staff of compassionate and knowledgeable individuals who respect what your family is experiencing and who go the extra mile to make an unfortunate diagnosis less stressful. Information and assistance were provided by The Mesothelioma Center at no cost to our family."

Lashawn

Mesothelioma patient’s daughter

Read Our Testimonials

Artificial Intelligence overly of CT scanner

Scientists in Scotland have developed a prototype imaging system using artificial intelligence that has proven effective with malignant mesothelioma, potentially revolutionizing the way patients will be treated in the future.

The pilot program could spark much-needed advances in diagnostics and therapeutics.

“Mesothelioma is such a complex, incredibly difficult disease,” Dr. Kevin Blythe, professor of respiratory medicine at University of Glasgow and respiratory physician at Queen Elizabeth University Hospital, told The Mesothelioma Center at Asbestos.com. “This could be a very important step toward helping patients in the future.”

The University of Glasgow and Canon Medical Research Europe worked together in developing the novel technology built around artificial intelligence, or AI. The computer software can detect and measure cancer cells more effectively than traditional imaging.

It could be used to more accurately – and quickly – assess a mesothelioma patient’s immediate response to drug treatments such as chemotherapy and immunotherapy.

AI Could Provide More Personalized Treatment

The project, which was launched in 2018, was focused intentionally on mesothelioma, a rare but aggressive malignancy, and one of the most difficult-to-measure with traditional CT scans.

Scotland, with a long history of shipbuilding and the use of asbestos in construction, has one of the world’s highest incidence rates of mesothelioma.

The findings are expected to provide a good foundation to produce similar tools for use in assessing more common cancers. Mesothelioma is typically more difficult to read than other tumors because of its more complex growth pattern.

“Measuring response with mesothelioma has always been incredibly difficult,” Blythe said. “In itself, artificial intelligence can’t change treatment, but it will help make better decisions with drug therapies.”

The system also will be used eventually to speed up the diagnostic process for mesothelioma, which could make a dramatic difference in future survival times. In the majority of cases today, mesothelioma is not diagnosed until the later stages, when treatment options are much more limited and mostly palliative.

Eliminating Human Error in Mesothelioma Assessment

The artificial intelligence cancer assessment tool has the potential to streamline clinical trials, making them less time-consuming, more accurate and less expensive, issues that often are cited as obstacles to new drug development for mesothelioma.

According to a recent press release from the University of Glasgow, the artificial intelligence was programed by inputting more than 100 mesothelioma CT scans. It responded by finding and measuring new tumors with acute accuracy, and without human input.

The program also would eliminate any human error. It should be better than humans in recognizing subtle changes that are invisible to the human eye.

Researchers believe the artificial intelligence tool will be available soon to help medical professionals everywhere find and measure mesothelioma with improved precision, which should lead to better, more personalized treatment.

“Accurate tumor volume measurements are much too time-consuming to perform by hand. Automating these measurements will open the way for clinical trials of new treatments by detecting even small changes in the tumor size,” said Dr. Keith Goatman, principal scientist at Canon Medical Research Europe. “Ultimately it could be used routinely in hospitals to decide the best treatment for each individual.”

Clinical findings from this project are expected to be published soon in one of the scientific journals, leading to the program dissemination. The project is part of Scotland’s Cancer Innovation Challenge.

“The speed and accuracy of the AI algorithm could have a wide-reaching impact on mesothelioma treatment,” Goatman said “This work is a strong first step towards real change in the treatment of all cancers – and not just mesothelioma.”